Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial

AMGN•2026-09-08

Late-stage lung cancer trial meets survival goal

Sept. 8 (Reuters) - AstraZeneca said on Tuesday its cancer drug Imfinzi combined with Amgen's targeted immunotherapy Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial.

Corrects headline to say Amgen-AstraZeneca drug combo, not AstraZeneca's drug combo.

Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial

Late-stage lung cancer trial meets survival goal

Related News

Rhode Island Energy conditionally selects 150 MW from Clearway northern Maine wind project

Destiny Tech100 CEO Prasad Sohail acquires USD 1.77 million in common shares

BUZZ-Lululemon up after falling 18% in prior session; new CEO takes charge

Kennametal director Richard J. Harshman acquires $151,050 of common shares

EU wheat eases as Ukraine war diplomacy assessed